Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Insmed Inc. Files Shelf Registration, Boosts Capital Flexibility & Investor Confidence

Insmed Inc. strengthens capital‑market footing with a new shelf registration and insider transparency, while its FDA‑approved ARIKAYCE and BRINSUPRI and promising respiratory, immunology, and rare‑disease pipelines offer investors a diversified grow…

Dr. Michael Chen

17/05/2026, 05:23

5 minutes to read

Merck KGaA Expands Supervisory Board to Boost Oncology Innovation Leadership

Merck KGaA expands its supervisory board to eight, adding oncology‑focused experts to boost drug development and regulatory strategy.

Dr. Michael Chen

16/05/2026, 22:37

3 minutes to read

Daraxonrasib Expanded Access: A New Hope for KRAS‑Mutant Pancreatic Cancer Patients

Revolution Medicines launches an expanded access program for daraxonrasib, a KRASG12D‑targeted agent boosting survival in pancreatic cancer patients with limited options.

Dr. Michael Chen

16/05/2026, 08:17

4 minutes to read

Bayer’s Crop Science Surge Drives 2026 Fiscal Momentum, Outpacing Expectations

Explore how Bayer AG’s Crop Science unit drives 2026 growth, from gene‑edited crops to AI irrigation, while boosting yields and community impact.

Dr. Michael Chen

14/05/2026, 22:31

4 minutes to read

Merck KGaA Boosts 2026 Outlook, Powered by Strong Q1 Semiconductor Surge

Merck KGaA raises 2026 outlook after strong Q1, driven by booming semiconductor sales boosting profits, while pharma remains steady.

Dr. Michael Chen

14/05/2026, 21:50

3 minutes to read

Thermo Fisher Leads Life‑Science Growth: Automation, AI‑IT & DNA‑Synthesis Breakthroughs

Thermo Fisher’s strategic edge in laboratory automation, life‑science IT & DNA‑synthesis shows how AI, cloud and regulatory‑compliance tools boost precision‑medicine pipelines.

Dr. Michael Chen

14/05/2026, 07:28

3 minutes to read

Merck KGaA Q1 2026 Earnings: Strong Finance, Voting‑Rights Shift & Precision‑Medicine Advances

Merck KGaA’s Q1 2026 earnings reveal a balanced financial picture, a modest voting‑rights shift, and promising oncology and diabetes pipelines poised for accelerated approval.

Dr. Michael Chen

13/05/2026, 20:31

4 minutes to read

China’s Healthcare Boom: Citi’s Insight on Pharma, CDMO Growth & Future Catalysts

Explore Citi’s in‑depth analysis of China’s booming healthcare sector—highlighting AI‑driven diagnostics, gene therapies, and CDMO growth that give investors a clear edge.

Dr. Michael Chen

13/05/2026, 06:25

5 minutes to read

Merck KGaA Thrives Amid EU Medicine Policy Shift & DNA‑Polymers Growth

Merck KGaA’s strategy blends EU‑support for essential medicine supply with a leading role in synthetic DNA and polymerase markets, showing how robust science and regulation drive growth.

Dr. Michael Chen

12/05/2026, 11:29

5 minutes to read

CSL Limited Faces $5B Impairment: Restructuring, Revenue Outlook and Cost‑Savings Plan

CSL Limited cuts profit forecasts after a $5B Vifor impairment, but still expects growth from Behring and Seqirus while targeting cost savings.

Dr. Michael Chen

11/05/2026, 23:48

5 minutes to read